NCT03485365 - A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2018

Primary Completion Date

September 12, 2022

Study Completion Date

September 12, 2022

Conditions

Pain, Inflammatory

Interventions

DRUG

GSK3858279 IV

GSK3858279 will be available as solution for injection to be administered via IV route.

DRUG

GSK3858279 SC

GSK3858279 will be available as solution for injection to be administered via SC route.

DRUG

Placebo matching to GSK3858279 (SC or IV)

Placebo will be available as sodium chloride solution to be administered via SC or IV route.

DRUG

Placebo matching to GSK3858279 (SC)

Placebo will be available as sodium chloride solution to be administered via SC route.

Trial Locations (5)

GSK Investigational Site, Berlin

GSK Investigational Site, Warsaw

GSK Investigational Site, Cambridge

GSK Investigational Site, London

GSK Investigational Site, Manchester